Guidehouse names Douglas Martin and Saul Helman as life sciences co-heads

18 March 2021 Consulting.us

Management consultancy Guidehouse has named Douglas Martin, MD, and Saul Helman, MD, as co-leaders of the firm’s biotech, pharma, and medtech consulting practice.

Martin and Helman, both of whom joined Guidehouse when the Washington-based firm acquired Navigant Consulting, will lead a life sciences practice that has been “refocused and restructured…to continue to innovate and serve as the trusted partner to life sciences companies worldwide,” said a release from Guidehouse.

Martin has more than 20 years of experience in consulting, private equity, venture capital, and investment banking, with a focus on the life sciences industry. He has deep expertise in therapeutic area strategy, pipeline and on-market product support, launch services, and business and corporate development.

Martin previously served as leader of the US commercial growth strategy team and as a partner in the life sciences practice. Prior to joining Navigant in 2014, Martin spent nearly 14 years at Leerink Partners (now SVB Leerink), a boutique investment bank and consulting firm, where he was a managing director.

Guidehouse names Douglas Martin and Saul Helman as life sciences co-heads

He started his consulting career at McKinsey & Company, where he spent over two years as an engagement manager focusing on life sciences clients.

Earlier in his career, Martin was an internal medicine resident at Brigham & Women’s Hospital. He holds an MD from the University of Pennsylvania and a BS in psychology from McGill University.

Helman has more than two decades of management and consulting experience in healthcare, biopharma, and medical devices. He specializes in developing and implementing healthcare compliance programs, and has extensive experience in litigation and investigation support, as well as expert witness testimony.

Helman joined Navigant in 2007, and most recently served as leader of the global compliance and regulatory practices. Prior to that, he was a director at KPMG and a director at pharma firm Eli Lilly & Co, where he focused on therapeutic area strategy, new product planning, and marketing.

He holds an MBA from Oxford Brookes University in the UK, as well as MD and BS degrees from the University of Witwatersrand in South Africa.

“Our priority is to enable life sciences companies to achieve and exceed their corporate growth and financial goals by creating a healthier society,” said Helman. “Together, our team of seasoned experts will continue to work with life sciences organizations to transform treatment paradigms in ways that demonstrate significant clinical and economic value, and ultimately improve patient outcomes.”

Guidehouse also announced that it has welcomed Ben Resnick as a new partner who will lead growth strategy for the Chicago and West Coast life sciences teams. He joins from Capgemini Invent, where he led the North America life sciences advisory practice.

“Guidehouse has built an international reputation as a trusted partner for life sciences companies seeking to build, manage, and protect their businesses,” Alicia Harkness, Guidehouse partner and health segment leader, said. “With experts like Doug, Saul, and Ben leading the way, we are proud to serve our clients with new innovative, integrated solutions and an expanded set of market offerings.”